The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss:

1. Increasing Awareness: Debunking common myths and misconceptions about HS.

2. Building Trust: Strategies for overcoming diagnostic delays and insufficient management.

3. Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities.

4. The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.

This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating these agents into their practice, and analyze the resulting impact on patient outcomes and their overall approach to AD management. Listen in as board-certified dermatologists, Mona Shahriari, MD and G. Michael Lewitt, MD discuss:

1. Overview of targeted topical therapies, including next generation topicals

2. Efficacy of targeted topicals compared to topical steroids

3. Safety, limitations, and compatibility with other therapies

4. How to integrate targeted topicals into clinical practice

5. Pearls for treating pediatric and adult patients across the indicated age range

This podcast is supported by an educational grant from Arcutis Biotherapeutics, Inc.

The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:

1. Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology

2. Long-term safety of topical therapies for chronic AD

3. Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial

4. Shifting the paradigm of topical AD care across patient populations

This is the third part of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." This episode, "Addressing Patient Concerns Regarding Treatment of Dermatoses Using Steroids," focuses on the importance of patient education and shared decision-making.

In this episode, supported by an educational grant from Arcutis, expert dermatologists Mona Shahriari, MD and Alexandra Golant, MD discuss how to effectively inform and de-escalate concerns from patients and caregivers regarding steroid treatments for atopic dermatitis.

Join us as we explore:

1. The risks and benefits of using topical steroids and non-steroidals.

2. How to involve patients in their treatment decisions.

3. Managing side effects from topical steroids, especially for patients with skin of color.

4. Tips for helping patients with daily AD care.

5. Pearls for patient education.

In the second installment of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," we're tackling a topic that's often misunderstood and highly challenging: Topical Steroid Withdrawal (TSW). Supported by an educational grant from Arcutis, this episode, "Topical Steroid Withdrawal – Myths vs Science," features expert dermatologists Dr Mona Shahriari, MD, and Dr Peter Lio, MD.

Join us as we separate fact from fiction and dive deep into:

1. The common pitfalls of overusing or misusing topical corticosteroids (TCS)

2. How to recognize the telltale signs and symptoms of TSW

3. Effective and compassionate strategies for managing TSW

4. The key to using TCS responsibly

5. Understanding when to pivot to targeted, non-steroidal treatments.

For those interested in the science behind TSW, we've included a link to a recent publication on the disease mechanism: Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD - PubMed

This is the first episode of a four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," supported by an educational grant from Arcutis. In this episode, "Steroidal vs Non-Steroidal Topicals – Case by Case Discussion," expert dermatologists, Mona Shahriari, MD and James Song, MD, discuss:

• Appropriate use of topical corticosteroids and targeted topicals for atopic dermatitis
• Benefits of topical corticosteroids and remaining unmet needs
• How new targeted topicals fit into the atopic dermatitis toolbox and improve adherence to therapy
• Case-based discussion of targeted topicals for the treatment of AD.

In this episode, entitled "JAK Inhibition for Treatment of Vitiligo," expert dermatologists, Dr Andrew Alexis, MD, MPH and Dr Erik Domingues, MD, FAAD, discuss the following topics: · Changing the culture of vitiligo care · Diagnosing vitiligo and associated comorbidities · Strategies for managing vitiligo and educating patients about treatment options · Setting patient expectations for the treatment process

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics:

• Mechanism of action for IL-31 inhibitor nemolizumab

• Clinical safety and efficacy data for nemolizumab for treatment of PN

• Strategies for prescribing IL-31 inhibitors in clinical practice

• Pearls for patient selection and addressing treatment challenges

This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, as they discuss the following topics:

• Setting the stage for treating a patient with EB

• Assessing EB severity and subtype to inform treatment

• Expert review of the current FDA-approved treatments and

• Strategies to close care gaps for EB patients

This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics:

1. Challenges in achieving treatment targets in AD

2. Therapeutic inertia and clinical implications of inadequate response

3. Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD

4. Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies